Benzinga··Vandana SinghEli Lilly's Omvoh Shows Durable Long-Term IBD Benefits, Bolstering Pipeline Confidence
Eli Lilly reports durable four-year efficacy data for Omvoh in IBD, with 63.5% ulcerative colitis remission and 92.4% Crohn's response rates, bolstering pipeline confidence.
LLYFDA approvalclinical trial